Literature DB >> 36268115

Effects of Purinergic Receptor Deletion or Pharmacologic Modulation on Pulmonary Inflammation in Mice.

Gregory S Whitehead1, Tadeusz P Karcz1,2, Dilip K Tosh3, Young-Hwan Jung3, Zhiwei Wen3, Ryan G Campbell3, Varun Gopinatth3, Zhan-Guo Gao3, Kenneth A Jacobson3, Donald N Cook1.   

Abstract

COVID-19 disease is associated with progressive accumulation of SARS-CoV-2-specific mRNA, which is recognized by innate immune receptors, such as TLR3. This in turn leads to dysregulated production of multiple cytokines, including IL-6, IFN-γ, CXCL1, and TNF-α. Excessive production of these cytokines leads to acute lung injury (ALI), which consequently compromises alveolar exchange of O2 and CO2. It is therefore of considerable interest to develop novel therapies that reduce pulmonary inflammation and stem production of pro-inflammatory cytokines, potentially for COVID-19 patients that are at high risk of developing severe disease. Purinergic signaling has a central role in fine-tuning the innate immune system, with P2 (nucleotide) receptor antagonists and adenosine receptor agonists having anti-inflammatory effects. Accordingly, we focused here on the potential role of purinergic receptors in driving neutrophilic inflammation and cytokine production in a mouse model of pulmonary inflammation. To mimic the effects of SARS-CoV-2-specific RNA accumulation in mice, we administered progressively increasing daily doses of a viral mimetic, polyinosinic:polycytidylic acid [poly(I:C)] into the airways of mice over the course of 1 week. Some mice also received increasing daily doses of ovalbumin to mimic virus-encoded protein accumulation. Animals receiving both poly(I:C) and ovalbumin displayed particularly high cytokine levels and neutrophilia, suggestive of both innate and antigen-specific, adaptive immune responses. The extent of these responses was diminished by genetic deletion (P2Y14R, P2X7R) or pharmacologic modulation (P2Y14R antagonists, A3AR agonists) of purinergic receptors. These results suggest that pharmacologic modulation of select purinergic receptors might be therapeutically useful in treating COVID-19 and other pulmonary infections. Not subject to U.S. Copyright. Published 2022 by American Chemical Society.

Entities:  

Year:  2022        PMID: 36268115      PMCID: PMC9578140          DOI: 10.1021/acsptsci.2c00128

Source DB:  PubMed          Journal:  ACS Pharmacol Transl Sci        ISSN: 2575-9108


  50 in total

Review 1.  A3 Adenosine Receptors as Modulators of Inflammation: From Medicinal Chemistry to Therapy.

Authors:  Kenneth A Jacobson; Stefania Merighi; Katia Varani; Pier Andrea Borea; Stefania Baraldi; Mojgan Aghazadeh Tabrizi; Romeo Romagnoli; Pier Giovanni Baraldi; Antonella Ciancetta; Dilip K Tosh; Zhan-Guo Gao; Stefania Gessi
Journal:  Med Res Rev       Date:  2017-07-06       Impact factor: 12.944

2.  The P2Y14 receptor of airway epithelial cells: coupling to intracellular Ca2+ and IL-8 secretion.

Authors:  Tobias Müller; Hans Bayer; Daniel Myrtek; Davide Ferrari; Stephan Sorichter; Manfred W Ziegenhagen; Gernot Zissel; J Christian Virchow; Werner Luttmann; Johannes Norgauer; Francesco Di Virgilio; Marco Idzko
Journal:  Am J Respir Cell Mol Biol       Date:  2005-08-18       Impact factor: 6.914

Review 3.  Nucleotide signalling during inflammation.

Authors:  Marco Idzko; Davide Ferrari; Holger K Eltzschig
Journal:  Nature       Date:  2014-05-15       Impact factor: 49.962

Review 4.  Vaccine development for emerging infectious diseases.

Authors:  Jean-Louis Excler; Melanie Saville; Seth Berkley; Jerome H Kim
Journal:  Nat Med       Date:  2021-04-12       Impact factor: 53.440

5.  In vivo phenotypic screening for treating chronic neuropathic pain: modification of C2-arylethynyl group of conformationally constrained A3 adenosine receptor agonists.

Authors:  Dilip K Tosh; Amanda Finley; Silvia Paoletta; Steven M Moss; Zhan-Guo Gao; Elizabeth T Gizewski; John A Auchampach; Daniela Salvemini; Kenneth A Jacobson
Journal:  J Med Chem       Date:  2014-11-25       Impact factor: 7.446

6.  Contribution of the Purinergic Receptor P2X7 to Development of Lung Immunopathology during Influenza Virus Infection.

Authors:  Victor H Leyva-Grado; Megan E Ermler; Michael Schotsaert; Ma G Gonzalez; Virginia Gillespie; Jean K Lim; Adolfo García-Sastre
Journal:  MBio       Date:  2017-03-28       Impact factor: 7.867

7.  Association of asthma and its genetic predisposition with the risk of severe COVID-19.

Authors:  Zhaozhong Zhu; Kohei Hasegawa; Baoshan Ma; Michimasa Fujiogi; Carlos A Camargo; Liming Liang
Journal:  J Allergy Clin Immunol       Date:  2020-06-06       Impact factor: 10.793

8.  Treatment of chronic neuropathic pain: purine receptor modulation.

Authors:  Kenneth A Jacobson; Luigino Antonio Giancotti; Filomena Lauro; Fatma Mufti; Daniela Salvemini
Journal:  Pain       Date:  2020-07       Impact factor: 7.926

Review 9.  SARS-CoV-2 infection: The role of cytokines in COVID-19 disease.

Authors:  Víctor J Costela-Ruiz; Rebeca Illescas-Montes; Jose M Puerta-Puerta; Concepción Ruiz; Lucia Melguizo-Rodríguez
Journal:  Cytokine Growth Factor Rev       Date:  2020-06-02       Impact factor: 7.638

10.  Predictive value of neutrophil to lymphocyte and platelet to lymphocyte ratio in COVID-19.

Authors:  Shiping Zhu; Lei Dong; Wanru Cai
Journal:  Crit Care       Date:  2020-08-28       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.